This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Oncology-focused bioinformatics firm M2GEN has entered a multi-year strategic collaboration with Zephyr AI to identify treatments and cures for cancer patients. Under the multiyear deal, Zephyr AI will license M2Gen’s RWD and will, in return, provide M2Gen will AI and machine learning technologies to enhance its products and services.
The new partnership will apply Mogrify’s cellular reprogramming and bioinformatics expertise to try to identify transcription factors – proteins which can turn specific genes on or off – that can be used to generate new cochlear hair cells. An estimated 1.57
We have fully equipped labs for all stages of drug discovery, including medicinal chemistry, cellular pharmacology, and molecular pharmacology, as well as an “ in silico ” lab for our computational chemistry, bioinformatics, and data mining activities. .
OSS, Netherlands , Nov.
They go into bioinformatics”. There is some pharmaceutical activity with older and well-to-do companies, but they’re more focused on licensing than development.”. They go into bioinformatics.”. There are a lot of scientists who want to better understand biology but don’t have the money to do it in wet settings.
There are different fields to explore as a clinical scientist — these include clinical bioinformatics, physiological sciences, pathology, medical physics and more. In addition, some clinical scientist jobs require you to be licensed or certified. What Field Can You Work in as a Clinical Scientist?
This impressive growth can be attributed to Fulgent’s distinctive chemistries and advanced proprietary bioinformatics pipeline, which have been instrumental in fueling the company’s rapid advancement in recent years. It is now progressing towards the submission of a Biologics License Application (BLA) by the end of 2023.
data processing systems that support bioinformatics modelling) and digital record systems (e.g. Digital technologies can cover a broad range of applications, and include mobile health (mHealth) tools (e.g. video consultations), health data analytics (e.g. digital applications, also referred to as “apps”, that function as patient diaries).
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.
Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. This system integrates mathematical modeling, biological science and bioinformatics and it could identify, report and mitigate new drugs and vaccines faster.
United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership.
License-related fees (5).
License-related fees (5).
The BREEZE study (NCT03950739) seeks to evaluate 45 patients on a stable dose of Tyvaso after switching to our new dry powder inhaler (DPI) form of treprostinil, which we licensed from MannKind Corporation.
.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content